A valine-to-isoleucine mutation at amino acid residue 197 of Glut2 or the equivalent residue 165 of Glut1 has been shown to impair glucose transport activity. This mutation was originally discovered in the Glut2 gene of a patient with type 2 diabetes. We investigated the mechanism of the effect of this mutation on transport activity via the analysis of Glut1 mutants expressed in Xenopus oocytes combined with cysteine substitution mutagenesis and the use of cysteine-reactive chemical probes. Aliphatic side chain substitutions at position 165 that were bulkier than the native valine residue inhibited glucose transport activity, whereas substitutions of less bulky side chains had little effect on transport, suggesting a role for steric hindrance. A cysteine residue was introduced at position 165 of a functional, cysteine-less Glut1 construct, and this mutant was then tested for inhibition of transport activity by a membrane-impermeant sulfhydryl-specific reagent (p-chloromercuribenzenesulfonate). p-Chloromercuribenzenesulfonate inhibited activity of the Cys 165 mutant when it was added to the external buffer but not when it was injected directly into oocytes, indicating that this residue is accessible from the external solvent but not from the cytoplasm. Competition experiments indicated that Cys 165 lies near the exofacial substrate-binding site or directly in the sugar permeation pathway. These data provide evidence that the side chain of Val 165 , which resides in the middle of transmembrane helix 5, juts into the aqueous permeation pathway of Glut1, probably between the exofacial substrate-binding site and the outer vestibule of the pathway.
Glut1 is the prototype member of the Glut family of membrane glycoproteins, which comprises four glucose transporter isoforms (Glut proteins 1-4) and a fructose transporter (Glut5) (1, 2) . Glut1 is perhaps the most extensively studied of all of the facilitated diffusion-type membrane transport systems. Its kinetic properties have been studied for over four decades in the human erythrocyte membrane (3, 4) , and more recently in a variety of cell types, including Xenopus oocytes (5, 6 ) and the muscle of transgenic mice overexpressing Glut1 (7) . Most of the kinetic observations on Glut1 are consistent with a simple alternating conformation mechanism for glucose transport (8) , although important transport anomalies have been observed in the human red blood cell that have not been adequately explained in terms of the simple carrier model (3) .
The amino acid sequence of Glut1 was deduced from analysis of cDNA clones isolated from human HepG2 (9) and rat brain (10) libraries. The human polypeptide comprises 492 amino acid residues, exhibits a molecular mass of 54,117, and bears a single N-linked oligosaccharide at Asn 45 . The 12-transmembrane helix topological model for Glut1, originally postulated on the basis of hydrophobicity analysis (9) , is strongly supported by enzymatic (9, 11) and immunologic (12) studies, and by a comprehensive glycosylation-scanning mutagenesis study (13) . A 12-transmembrane helix model has also been experimentally verified for the Lac permease of Escherichia coli (14) , a protein that belongs to the same superfamily as the mammalian Glut proteins, lending indirect but additional evidence in support of the 12-transmembrane helix model for Glut1 and other members of the superfamily.
We noted that 5 of the 12 transmembrane segments of Glut1 could form amphipathic ␣-helices and postulated that several of these helices might cluster together in the membrane to form the walls of an aqueous pathway through which sugar substrates traverse the fatty acyl core of the lipid bilayer (9) . Additionally, we suggested that hydroxyl and amide side chains within these amphipathic helices (helices 3, 5, 7, 8, and 11) might form the glucose-binding site or sites within the membrane via hydrogen bonding to glucose hydroxyl groups. In support of this hypothesis, experimental evidence has been presented that Gln 282 , within helix 7 (15) , and Gln
161
, within helix 5 (16), form part of the exofacial substrate-binding site.
We previously reported that a mutation discovered in the Glut2 gene of a diabetic patient (Val 197 3 Ile) severely disrupts activity of the Glut2 protein expressed in Xenopus oocytes, and that the corresponding mutation in Glut1 (Val 165 3 Ile) also abolished transport activity (17) . This valine residue lies within transmembrane helix 5, approximately one helical turn distant from Gln 161 . The effect of this mutation was completely unexpected, given the highly conservative nature of the substitution, and the unreactive nature of the valine side chain, especially in the context of a hydrophobic environment where valine cannot participate in hydrophobic interactions with other amino acid side chains that might otherwise stabilize transporter structure in the context of an aqueous environment.
To investigate the role of Val 165 in the structure and function of Glut1, we used an experimental approach involving cysteine substitution mutagenesis combined with sulfhydryl-reactive chemical probes. Khorana and colleagues (18, 19) were the first to use this approach to explore the structure and function of a membrane transporter, and the approach has subsequently been exploited in various permutations to investigate the structure-function relationships of a variety of membrane transporters (18 -24) and ion channels (25) (26) (27) (28) . Our data suggest that Val 165 lies within the aqueous sugar translocation pathway of Glut1, in close proximity to both the exofacial substrate-binding site and the outer vestibule of the transporter. These observations lend additional support to our model concerning the importance of helix 5 in transporter catalytic activity (9) .
EXPERIMENTAL PROCEDURES
Procedures for the site-directed mutagenesis and sequencing of human Glut1 cDNA and the in vitro transcription and purification of Glut1 mRNAs (29) , isolation, microinjection, and incubation of Xenopus oocytes (30) , preparation of total oocyte membranes and laser confocal immunofluorescence microscopy of sectioned oocytes (31), SDS-polyacrylamide gel electrophoresis and immunoblotting with Glut1 C-terminal antibody (16) , and 2-deoxyglucose uptake measurements (5) have been described in detail previously.
Stage 5 Xenopus oocytes were injected with 50 ng of wild-type or mutant Glut1 mRNA. Three days after injection, groups of ϳ30 oocytes were incubated for 15 min in the presence or absence of the indicated concentrations of p-chloromercuribenzoate (pCMB), 1 p-chloromercurisulfonate (pCMBS), iodomethane, or iodoacetate in Barth's saline at 22°C. The 100-fold concentrated reagent stocks were prepared in 50% dimethyl sulfoxide, and control oocytes were treated with the appropriate concentration of vehicle alone. In some experiments, sugars (2-deoxyglucose, ethylidene glucose, D-glucose) were included in the incubation solution at 200 mM to test for their ability to delay the sulfhydryl reaction. After the 15-min incubation, the oocytes were washed three times in Barth's saline and then used for the determination of [ 3 H]2-deoxyglucose uptake (50 M, 30 min at 22°C).
RESULTS
We reported previously that the highly conservative substitution of an isoleucine for Val 165 of Glut1, a residue that lies in the middle of transmembrane helix 5, dramatically reduces transport activity (17) . Val 165 lies one helical turn distant from Gln 161 , a residue that appears to be involved in forming the exofacial substrate-binding site of Glut1 (16) (see Fig. 1 ). We reasoned that the isoleucine side chain, which bears an extra methylene group compared with valine, might sterically inhibit interaction between glucose and the amide side chain of Gln 161 as a result of its greater bulk. We tested this hypothesis by examining the effect of other amino acid substitutions at position 165 on transport activity. If the hypothesis is correct, bulkier aliphatic side chain substitutions at position 165 should inhibit activity, whereas less bulky side chains should have little if any effect on transport function.
The aliphatic series of amino acid substitutions at position 165 of human Glut1 that were generated and analyzed are listed in Table I . The mutant cDNAs were transcribed into mRNAs that were then injected into Xenopus oocytes. Transporter expression and function were analyzed 3 days after injection. Western blot analyses of total oocyte membranes demonstrated that the relative level of protein expression varied somewhat among the mutants and wild-type Glut1 ( Fig.  2A ) and also varied from one experiment to another, as is often the case with the oocyte expression system. However, laser confocal immunofluorescence microscopy of oocyte sections demonstrated that all of the mutants were consistently expressed in the plasma membrane as efficiently as wild-type Glut1 (Fig. 2B ). 2-Deoxyglucose uptake measurements showed that amino acid side chain substitutions at position 165 that were bulkier than valine (leucine, isoleucine) inhibited activity of Glut1 by 76 -82%, whereas side chain substitutions less bulky than valine (glycine, alanine) had little or no effect on transport activity (Fig. 3) . Although there was a tendency for the alanine substitution mutant to display a lower activity than wild-type Glut1, the difference was not statistically significant (p ϭ 0.0543).
The above observations, coupled with the fact that Val 165 lies approximately one helical turn distant from a residue that appears to interact directly with glucose during its passage through the membrane, suggest that Val 165 may extend into the aqueous pathway by which glucose traverses the lipid bilayer, and that bulky substitutions at this position either inhibit substrate interaction with Gln 161 or interfere with transport activity in some other way. To determine more directly whether Val 165 lies exposed in the aqueous transmembrane pathway formed by Glut1, we first created a Glut1 molecule devoid of cysteine residues by employing site-directed mutagenesis to change all six native cysteine residues to either 1 The abbreviations used are: pCMB, p-chloromercuribenzoate; pC-MBS, p-chloromercuribenzenesulfonate; C-less, Glut1 molecule in which all six native cysteine residues were changed to either glycine or serine. glycine or serine residues (see Table I ). The resultant cysteineless Glut1 molecule (C-less Glut1) exhibited 77 Ϯ 16% of wildtype Glut1 transport activity when expressed in Xenopus oocytes as indicated by [ 3 H]2-deoxyglucose uptake (mean Ϯ S.E., four independent experiments), confirming that none of the native Glut1 cysteine residues is essential for transport function (32) . We then introduced a single cysteine into C-less Glut1 at position 165 by site-directed mutagenesis. The Cys 165 mutant exhibited 55 Ϯ 11% of the glucose transport activity of wild-type Glut1 (mean Ϯ S.E., four independent experiments), a sufficient level of activity to allow an accurate assessment of the effect of cysteine-specific reagents on transport activity. Considering that residue 165 resides in the middle of transmembrane helix 5, if the Cys 165 C-less mutant reacts with a membrane-impermeant, cysteine-specific reagent, this would be highly suggestive that this residue lies within an aqueous transmembrane channel accessible from the extracellular fluid. pCMBS was used as the membrane-impermeant sulfhydrylspecific reagent, and the structurally similar pCMB served as a membrane-permeable control for reactivity of Cys 165 (see Fig.  4 ). Fig. 5A demonstrates that preincubation of oocytes in the presence of 0.5 mM of either reagent inhibited 2-deoxyglucose uptake activity of wild-type Glut1 by ϳ50%, consistent with a previous report demonstrating that this inhibition is due to reactivity with the exofacially disposed Cys 429 (33) . In contrast, the activity of C-less Glut1 was minimally effected by pCMB or pCMBS. However, when oocytes expressing the Cys 165 mutant were preincubated with pCMB or pCMBS, transport activity was inhibited by 78 and 89%, respectively. Fig. 5B demonstrates that inhibition of Cys 165 activity by both reagents was dose-dependent, although the percentage maximal inhibition observed with either reagent varied from ϳ60% to ϳ90% in independent experiments (data not shown). To determine whether Cys 165 is accessible from the cytoplasmic compartment, pCMB and pCMBS were injected into oocytes prior to measurement of 2-deoxyglucose uptake. Fig. 5C shows that neither pCMB nor pCMBS was able to inhibit the activity of C-less Glut1 or the Cys 165 mutant when injected into the cytoplasm of oocytes. These data indicate that, during the transport cycle, Cys 165 is accessible from the external solvent but not from the cytoplasmic compartment, suggesting that this residue may lie within or near the exofacial vestibule of the aqueous permeation pathway.
If Cys 165 lies in close proximity to the exofacial substratebinding site or directly in the sugar translocation pathway, then sugar substrates might compete with and delay the covalent reaction of pCMBS with Cys 165 . A complete inhibition of the reaction would not be expected, because sugar ligand binding is a transient, non-covalent interaction. Fig. 6 demonstrates that sugar substrates can indeed complete with and delay the interaction of pCMBS with Cys 165 . L-Glucose was
TABLE I Mutations introduced into wild-type or C-less Glut1
Mutations were created by oligonucleotide-mediated site-directed mutagenesis as described previously (16) . The first six mutations listed were introduced into wild-type human Glut1 cDNA to create cysteineless (C-less) Glut1. The seventh mutation listed was introduced into C-less Glut1 cDNA to create the Cys 165 C-less mutant. The last four mutations listed were introduced into wild-type human Glut1 cDNA to test the effect of aliphatic side chain size on transport activity.
Residue no.
Amino
FIG. 2. Expression of Glut1 protein in Xenopus oocytes. Stage 5
Xenopus oocytes were injected with 50 ng of wild-type or mutant Glut1 mRNAs, and 3 days later oocytes were used to prepare total membrane fractions for immunoblot analysis or for visualization of Glut1 via indirect immunofluorescence laser confocal microscopy. A, immunoblot with 20 g of total oocyte membrane protein loaded per lane. Rabbit antiserum A674 raised against the C-terminal 15 residues of human Glut1 was used at 1:500 dilution. The mobilities of molecular weight markers are indicated on the left. The three lanes on the right labeled 10 -30 ng were loaded with the indicated amount of human erythrocyte glucose transporter protein as standards. B, oocytes expressing wildtype or mutant Glut1 protein were frozen, sectioned, and stained with A674 IgG (10 g/ml), followed by fluorescein-conjugated goat antirabbit IgG (0.37 g/ml). Sections were visualized using a Zeiss Axioplan fluorescence microscope interfaced with a Bio-Rad MRC 1024 laser confocal imaging system. used as an osmotic control that lacks affinity for Glut1-binding sites. The relative efficacy of the different sugars at competing out the pCMBS reaction parallels their relative affinity (1/K m ) for Glut1, i.e. 2-deoxyglucose Ͼ ethylidene glucose Х D-glucose (8) . Additionally, the observation that the non-transported Glut1 exofacial ligand, ethylidene glucose, inhibited the reaction of pCMBS with Cys 165 indicates that interaction with the exofacial substrate-binding site is sufficient to cause inhibition, and that inhibition was not the result of transport into the cytoplasm or binding to the inward-facing substrate-binding site.
pCMBS and pCMB were used as sulfhydryl reactive reagents in the above experiments, in part because these molecules bear some resemblance to hexose molecules in overall size and shape (see Fig. 4 ). To determine whether there are structural constraints on molecules that have access to Cys 165 , we examined the ability of two other sulfhydryl-reactive reagents, both smaller in size than either pCMB or pCMBS, to interact with Cys 165 . Fig. 7A demonstrates that neither methyliodide nor iodoacetate inhibited transport activity of the Cys 165 C-less mutant. Because this lack of inhibition could be due to the inability of the reagents to gain access to Cys 165 , or to the inability of the methylated or carboxymethylated cysteine residue to inhibit transport activity, we performed the experiment shown in Fig. 7B . In this experiment, oocytes expressing the Cys 165 C-less mutant were first incubated with either methyl iodide or iodoacetate, rinsed with buffer to remove the reagents, and then incubated with pCMBS under conditions that normally elicit inhibition of transport activity. If the iodine reagents react with Cys 165 but the reactions do not inhibit transport, then subsequent incubation with pCMBS should not result in transport inhibition of the Cys 165 C-less mutant, because the sulfhydryl group would already have formed adducts with the iodine reagents. The data in Fig. 7B show that subsequent incubation with pCMBS did result in inhibition of transport activity, indicating that the iodine reagents did not have access to Cys 165 within the permeation pathway of Glut1.
DISCUSSION
The experiments described herein identify an amino acid residue that appears to lie within the sugar translocation pathway of Glut1. This residue was originally identified because of its alteration in the GLUT2 gene of a patient with type II diabetes (34) . The valine-to-isoleucine mutation at position 197 of Glut2 and at the equivalent position 165 of Glut1 dramatically reduced transport function of the respective isoforms (17) . The unexpected effect of this mutation on transport activity motivated the present studies to determine the role of this residue in transporter function. Although Val 165 is unlikely to be directly involved in the binding of sugar substrates or in transporter conformational changes given its unreactive aliphatic side chain and in light of the results described here, it does appear to lie within the sugar translocation pathway in the vicinity of the exofacial sugar-binding site. 
FIG. 5. Effect of pCMB and pCMBS on transport activity.
A, 3 days after injection of mRNAs, groups of 20 -30 oocytes were incubated in the presence or absence of 0.5 mM pCMB or pCMBS in Barth's saline at 22°C. Oocytes were washed three times in Barth's saline and then subjected to 2-deoxyglucose uptake measurements under the conditions described in the legend to Fig. 3 . Results are expressed as mean Ϯ S.E. The data shown represent one of three independent experiments. Sham indicates results obtained with water-injected control oocytes; WildType represents unaltered human Glut1; C-less represents the cysteineless Glut1; Cys165 represents the Val 165 3 Cys mutant in the C-less background. B, oocytes expressing the Cys 165 C-less mutant were incubated for 15 min in the indicated concentration of pCMB or pCMBS in Barth's saline, washed three times in Barth's saline, and then subjected to 2-deoxyglucose uptake measurements as described in the legend to Fig. 3 . C, groups of 20 -30 oocytes expressing the C-less mutant or the Cys 165 mutant in the C-less background were injected with 50 nl of a solution of either 12.5 mM pCMB, 12.5 mM pCMBS, or 25% dimethyl sulfoxide (DMSO, control) and 15 min later subjected to 2-deoxyglucose uptake measurements as described in the legend to Fig. 1 . The final concentration of pCMBS or pCMB within the oocyte was ϳ1.25 mM, assuming uniform dispersion. Results are expressed as mean Ϯ S.E. The data shown represent one of four independent experiments. conformational changes.
Yan and Maloney (21), using a cysteine substitution experimental approach, have defined three distinct regions within putative transmembrane helix 7 of the bacterial glucose 6-phosphate antiporter, UhpT. They discovered that amino acid residues were either accessible to pCMBS only in intact cells, accessible only in inverted membrane vesicles, or accessible in both circumstances, depending on their relative location within the transmembrane helix. Residues close to the exoplasmic membrane face fell into the first category, residues close to the cytoplasmic membrane face fell into the second category, and residues near the middle of the helix fell into the third category. They interpreted their observations in terms of the classic single-site membrane carrier model (3, 4) , where one would expect amino acid residues involved directly in substrate binding (in the middle of helix 7 in the case of UhpT) that become exposed to both aqueous compartments during the course of the transport cycle. Residues that lie on the exofacial side of this region may only be exposed to the exoplasmic compartment, and residues that lie endofacial to this region may only be exposed to the cytoplasmic compartment. Their data provide compelling physical evidence for a general model of facilitative membrane transport derived solely on the basis of kinetic transport data.
The observation that Cys 165 in C-less Glut1 was accessible to pCMBS from the external medium but not from the cytoplasm suggests that this residue lies in the outer vestibule of Glut1 that does not become exposed to the cytoplasm during transporter conformational changes accompanying the transport cycle. The negative result obtained after injecting the reagent into oocytes must be interpreted with caution, however. It is possible that the intracellular pCMBS did not react with the cysteine residue at position 165 for a reason other than inaccessibility of the side chain. For example, there may be a large surplus of intracellular sulfydryl groups that affectively compete for reaction with the pCMBS. Cys 165 lies only one helical turn distant from a residue that appears to be directly involved in exofacial substrate binding, and also appears to lie in a structurally exclusive environment, given that iodomethane and iodoacetate do not have access to this residue. If one assumes that the Cys 165 side chain is inaccessible to intracellular substrate, as suggested by the pCMBS injection experiment, then Val 165 most likely lies at an intermediate position between the outer vestibule of Glut1 and the region of helix 5 involved directly in binding exofacially disposed glucose.
Regardless of the exact mechanism of the inhibition at Val 165 , the results reported here lend additional support to our original simplified structural model for Glut1 in which helix 5, along with other amphipathic helices, participates in forming an aqueous transmembrane channel, only accessible from one membrane face at any instant, and containing one or more substrate-binding sites (35) . Interestingly, helix 5 of the Lac permease of E. coli has been proposed to play a direct role in the transport of disaccharides. The Lac permease belongs to the 12 transmembrane helix transporter superfamily along with the mammalian Glut proteins, but much more is known about the structure/function relationships of the Lac permease compared with Glut1. Based on a variety of data, Kaback (36) has proposed that lactose is transported across the permease through a pocket or channel formed by helices 5, 7, and 8, and that Cys 148 and Met 154 within helix 5 are in direct contact with lactose during transport. It is tempting to speculate that overall helix bundling is conserved in all members of the 12 transmembrane helix superfamily, and that these same helices compose the sugar translocation pathway in Glut1. This would be FIG. 6 . Effect of sugar substrates on pCMBS-induced transport inhibition. Groups of 20 -30 oocytes expressing the Cys 165 mutant in the C-less background were incubated in the presence of 0.5 mM pCMBS and 200 mM of the indicated sugar in Barth's saline for either 1, 2, or 5 min at 22°C. After washing three times in Barth's saline, the oocytes were subjected to 2-deoxyglucose uptake measurements as described in the legend to Fig. 3 . L-Glucose served as an osmotic control with no affinity for Glut1. Values represent mean Ϯ S.E. The data shown represent one of four independent experiments.
FIG. 7. Cys
165 is inaccessible to iodomethane or iodoacetate. A, groups of 20 -30 oocytes expressing the Cys 165 mutant in the C-less background were incubated in the presence of 0.5 mM iodoacetate or 15 mM iodomethane for 15 min at 22°C, washed three times, and then subjected to [ 3 H]2-deoxyglucose uptake measurements as described in the legend to Fig. 3 . B, groups of 20 -30 oocytes expressing the Cys 165 mutant in the C-less background were incubated in the presence of 0.5 mM iodoacetate or 15 mM iodomethane for 15 min at 22°C, washed three times in Barth's saline, incubated in the presence of 0.5 mM pCMBS for 15 min, washed three times in Barth's saline, and then subjected to [ 3 H]2-deoxyglucose uptake measurements as described in the legend to Fig. 3 . The control group was subjected to the same physical manipulations but was incubated in the absence of any inhibitors. The iodomethane and iodoacetate groups received the initial incubation in the respective iodo compounds and a control second incubation in buffer only. Values are expressed as mean Ϯ S.E. The data shown represent one of three independent experiments. DMSO, dimethyl sulfoxide.
consistent with existing data that Gln 282 in helix 7 and Gln 161 in helix 5 participate in exofacial substrate binding.
